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SUMMARY
Intrusive thoughts about cancer, often identified as ‘cancer-specific worries’ or ‘cancer-specific distress’, have been
postulated to be associated with dysfunction in women at increased risk of developing breast or ovarian cancer.
The current study discusses the development and validation of a measure designed to assess women’s perceptions
of the interference such worries create in their daily functioning. Analyses revealed that approximately two-thirds
of a high-risk breast cancer clinic sample perceived worries about breast cancer as interfering with their functioning
across a variety of life domains. Multiple regression analyses indicated that worry interference scores predicted
Profile of Mood States (POMS) Anxiety and Confusion, and Short Form-36 (SF-36) Role-Emotional and Mental
Health scores after the effects of other variables such as frequency of worry about breast cancer, and having a
family history of cancer had been considered. Women who perceived their worries as interfering with their
functioning reported higher levels of anxiety and confusion, and diminished mental health and role functioning.
The results add to the expanding area of anxiety/distress in at-risk populations by providing (1) a direct measure
of the perceived interference associated with breast cancer-specific thoughts, (2) a validation of the measure via its
associations with standard measures of emotional distress and health functioning, and (3) evidence of the
measure’s incremental predictive value in explaining distress and quality of life, after consideration of background
variables, such as having a family history of cancer. Copyright © 2001 John Wiley & Sons, Ltd.
INTRODUCTION
Despite advances in breast cancer prevention,
183000 women will be diagnosed with breast can-
cer in the United States in the year 2000 (Ameri-
can Cancer Society, 1999). Given the known
impact of this disease on quality and length of
life, a great deal of research has been conducted
on the distress experienced by women with breast
cancer. Many studies have focused on identifying
the degree of distress present, factors that may
contribute to higher levels of distress, and strate-
gies for ameliorating the deleterious effects of
distress in this population (Leinster et al., 1989;
Fallowfield et al., 1990; Payne et al., 1999).
More recently, researchers have focused efforts
on identifying factors that may be associated with
the presence of depression or anxiety in women at
the time they are diagnosed with breast cancer, as
well as factors that may result in the continued
presence of anxiety and depression during recov-
ery. In a recent study, Epping-Jordan et al. (1999)
reported that low optimism and emotion-focused
coping predicted anxiety and depression at diag-
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nosis, while intrusive thoughts and optimism were
predictive of anxiety and depression at 3- and
6-months post-diagnosis, respectively.
Another factor that appears to be associated
with higher levels of distress in women with and
without cancer is having a family member who
has had cancer (Kash et al., 1992; Lerman et al.,
1993; Valdimarsdottir et al., 1995). In these stud-
ies, approximately one out of four women had
levels of distress that would potentially benefit
from a psychological intervention (Kash et al.,
1992), while approximately one out of three re-
ported that their daily lives were affected by wor-
ries about breast cancer (Lerman et al., 1993).
Consequently, both family history and intrusive
thoughts or worries about breast cancer appear to
play important roles in the development and
maintenance of anxiety and depression both in
women currently diagnosed with, as well as those
at increased risk for, breast cancer.
At present, genetic testing has become increas-
ingly utilized to identify women at increased risk
for breast and ovarian cancer. Numerous studies
have reported on the likelihood of being diag-
nosed with breast or ovarian cancer during one’s
lifetime following identification of the individual
as a carrier of a deleterious mutation in the
BRCA1 or BRCA2 genes (Easton et al., 1993;
Ford et al., 1994; Miki et al., 1994; Phelan et al.,
1996; Struewing et al., 1997). As the literature on
breast cancer genetics has become more refined,
many studies have begun to document the emo-
tional distress that may accompany being at high
risk for breast or ovarian cancer (Audrain et al.,
1997; Ritvo et al., 1999, 2000). Paralleling studies
on breast cancer patients, the results of studies
focused on the high-risk population reveal that
although women at suspected risk for having in-
herited a mutated breast or ovarian cancer suscep-
tibility gene (BRCA or other) have average levels
of depression and anxiety (Zakowski et al., 1997;
Schwartz et al., 1999), there remains a proportion
of women who exhibit significant distress that
may interfere with their functioning (Ritvo et al.,
1999, 2000).
Since it appears that on average, women at
increased risk for heritable breast or ovarian can-
cer do not evidence high levels of global distress,
the focus has shifted toward an examination of
‘cancer-specific’ distress. Research in this area has
primarily been in the form of questions about the
intrusiveness of thoughts about cancer during the
previous week. The focus is variously on the
individuals’ worries about having a diagnosis of
breast or ovarian cancer and its consequences or
on having a family history of breast cancer (Ler-
man et al., 1995; Schwartz et al., 1995; Croyle et
al., 1997; Zakowski et al., 1997). Unfortunately,
responses that individuals may have (such as
thought intrusions or avoidance) to a stressful
event are not, by themselves, equivalent to or
synonymous with distress, ‘cancer-specific’ or other-
wise. We interpret intrusions as cognitive events
that may or may not result in emotional distress
depending on how they are appraised. It is possi-
ble that general distress in women at increased
risk for breast cancer is not elevated and that
intrusive thoughts, although present, are neither
disruptive nor distressing. We also suggest, how-
ever, that women at risk may perceive cancer-
specific intrusive thoughts as interfering with their
functioning and, therefore, may interpret them as
distressing. As such, before cancer-specific intru-
sive thoughts are equated with distress, it may be
useful to measure (1) women’s perceptions of the
impact of such intrusive thoughts on multiple
areas of functioning, and (2) the degree of associ-
ation between this newly-measured impact on
functioning and standard measures of dysfunction
and distress.
Although recent research has demonstrated that
women at increased risk for breast cancer experi-
ence cancer-specific worries and intrusive
thoughts (Baider and De-Nour, 1997; Zakowski
et al., 1997; Epping-Jordan et al., 1999), and have
functioning that appears to be disrupted in a
variety of areas (Wellisch et al., 1991, 1992), little
research has measured the degree to which cancer-
specific intrusive thoughts are perceived as disrup-
tive by the women who experience them. The
research that has been done in this area has used
single-item Likert scales to assess the perceived
global impact of cancer worries and intrusive
thoughts on functioning (Easterling and
Leventhal, 1989; Lerman et al., 1991). More
specifically, Easterling and Leventhal (1989) asked
women at increased risk to rate the impact cancer
worry had on their ‘other thoughts and activities’,
while Lerman et al. (1991) asked women to rate
the impact of cancer worry on ‘mood and daily
functioning’. While this information is helpful in
that it provides evidence of a perceived associa-
tion between dysfunction and cancer-specific cog-
nitive processes, single-item scales are limited in
the amount of information they convey. We hy-
pothesized that a more detailed measure would
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allow for more variability in responses, thereby
increasing the descriptive and predictive value of
the construct of worry interference, and allowing
for a more detailed analysis of putative areas of
impairment. To this end, we set out in 1994 to
develop a measure to determine whether patients
attending a newly-founded breast and ovarian
cancer risk evaluation clinic perceived their can-
cer-specific thoughts as interfering with their func-
tioning in a number of areas. We expected some
variability in women’s responses to such a ques-
tionnaire, and hypothesized that increased inter-
ference would be positively related to standard
measures of dysfunction and mood disturbance.
METHOD
Participants
Individuals are both self-referred and referred
by medical professionals to the University of
Michigan Breast and Ovarian Cancer Risk Evalu-
ation Program (BOCREP) if they have a positive
family history of breast or ovarian cancer in one
or more close relatives, or a constellation of other
personal risk factors leading to a presumed in-
creased risk profile, as determined by the referral
source. These patients are not otherwise part of
previously assembled familial cancer high-risk co-
horts; they have not been subjects in previous
cancer genetics research and they were not invited
to come to clinic for research purposes. Therefore,
while some of these women may be at high-risk
for breast or ovarian cancer, they represent a
heterogeneous group of women attending a breast
and ovarian risk evaluation clinic as opposed to
typical familial cancer high-risk cohorts or pa-
tients identified exclusively through fixed eligibil-
ity criteria for research. A total of 290 women
attended the clinic between February 17 1995 and
December 31 1999. Per clinic protocol, all of these
women returned screening packets that included
the Worry Interference Scale (WIS) prior to their
appointment and were subsequently evaluated by
a medical oncologist and genetic counselor. Of
these 290 women, 205 completed all items of the
WIS. Following their initial genetic counseling
sessions, 88 women proceeded with genetic testing
after being identified as high risk based on a
pedigree analysis revealing a high likelihood of
the presence of a mutation in a cancer susceptibil-
ity gene being present in the family. All 88 of
these women received their testing results during a
second counseling session conducted 1 month
later. Repeat WIS data were requested one month
post-counseling and returned by 67 women. Table
1 presents characteristics of participants.
Measures
Clinic Questionnaire (CQ). The CQ is a demo-
graphic measure provided to all patients prior to
their arrival at the BOCREP. Individuals are
asked to answer questions that provide informa-
tion on basic demographics, medical and lifestyle
factors, personal and family history of breast
cancer, and cancer screening practices.
Profile of Mood States (POMS). The POMS is
a 65-item self-report questionnaire that measures
mood using six scales: Tension–Anxiety, Depres-
sion–Dejection, Anger–Hostility, Vigor–Activity,
Fatigue–Inertia, and Confusion–Bewilderment
(McNair et al., 1971, 1981). Respondents are
asked to rate the degree to which an adjective has
applied to them during the past week on a five-
point scale ranging from 0 ‘not at all’ to 4 ‘ex-
tremely’. A Total Mood Disturbance scale can be
computed by summing the subscale scores,
weighting Vigor negatively. The POMS has
proven reliability and validity and has been used
in research with a variety of cancer populations
(McNair et al., 1971; Lerman and Schwartz, 1993;
Schwartz et al., 1995).
Medical Outcomes Surey Short Form 36 (SF-
36). The SF-36 is a 36-item questionnaire assess-
ing quality of life (QOL) and functioning across a
variety of domains (Ware, 1993). It is composed
of eight scales including physical functioning, so-
cial functioning, bodily pain, and mental health.
A scale total is obtained by summing the re-
sponses to each item within the scale. Subse-
quently, transformed scores are obtained by
taking the total score, subtracting the lowest pos-
sible total score and dividing by the possible total
score range. This number is then multiplied by
100 in order to obtain a transformed score that is
between 0 and 100. Transformed scores are re-
ported in the current article. The SF-36 was cho-
sen over several more specific measures of quality
of life (e.g. the Functional Assessment of
Cancer Therapy—FACT—or Functional Living
Copyright © 2001 John Wiley & Sons, Ltd. Psycho-Oncology 10: 349–360 (2001)
P.C. TRASK ET AL.352
Table 1. Demographic characteristics of sample (n=290)





Native American 1 0.3
1 0.3Hispanic
2 0.7Asian









24 8.3Separated, divorced, or widowed
75 25.8Unknown, not asked, missing or other
Education
29Completed or attended high school 9.9
87 30.0Completed or attended college
98 33.8Completed or attended graduate school









54Did not report 18.6
Index-Cancer—FLIC) because of the desire to
obtain a measure of initial health functioning
when individuals may not have a diagnosis of
cancer. It has demonstrated adequate reliability
and validity (Ware, 1993).
Worry Interference Scale (WIS). The WIS is a
seven-item self-report measure developed by the
authors to assess the degree to which thoughts
about breast cancer are perceived as interfering
with the respondents’ daily functioning. It is
imbedded within a larger questionnaire that also
assesses perceived risk, intent to undergo genetic
testing, and frequency of worry about getting
breast cancer. The WIS scale items assess disrup-
tions in sleep, work, concentration, relationships,
having fun, feeling sexually attractive, meeting
family needs, and reproductive decisions. Addi-
tional items assess participants’ abilities to speak
with their partners about their concerns, their
partners’ abilities to be understanding, and fre-
quency of participants’ worries about their chil-
dren’s or grandchildren’s chances of developing
breast cancer. As noted in the discussion of the
scale development, these latter three items were
removed from the final scale. All items are as-
sessed on a five-point multiple-choice scale rang-
ing from 1 ‘not at all’ to 5 ‘a lot’. As such, the
range of scores on the total scale is 7–35. Exam-
ples of items include ‘Fears of developing breast
cancer have affected my relationships with
others’, ‘Thoughts of breast cancer have affected
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my ability to sleep’, and ‘Worries about breast
cancer have affected my ability to meet the needs
of my family’. A ‘not at all’ response is considered
to mean either that the respondent does not expe-
rience worry about getting breast cancer or that
worries about breast cancer do not interfere with
her functioning. Validity and reliability data, as
well as information on scale development are
provided as part of the results of this report.
Frequency of worry about breast cancer is mea-
sured on the same five-point scale as the interfer-
ence items, with responses ranging from 1 ‘not at
all’ to 5 ‘a lot’. Results of analyses conducted with
perceived risk and intent to undergo genetic test-
ing are currently being prepared for a future
manuscript and will not be presented here.
Procedure
Upon making initial contact with the
BOCREP, individuals are sent a questionnaire
package that includes the CQ and the WIS (Time
1). Returned questionnaires are examined and
appointments are made for those women who
appear to have concerns that can be addressed by
the clinic. At the time of the appointment, and
before counseling, individuals complete a ques-
tionnaire package that includes the POMS and
SF-36, among other measures. In the current
study, following completion of these question-
naires, individuals are provided with risk assess-
ment, genetic counseling, and risk management
options; in the course of the session, if pertinent,
a discussion of whether they desire and/or qualify
for genetic testing ensues. Blood is drawn for
those who are interested in and qualify for testing.
One month following their appointment, patients
are asked to complete a second package that
includes the WIS (Time 2) and to return the
package by mail. If genetic testing has taken
place, patients are provided the results in a face-
to-face post-test counseling session. In the current
study, 290 women provided Time 1 questionnaire
data, 205 of whom provided complete WIS data.
Of these, 67 returned Time 2 follow-up data.
RESULTS
WIS scale deelopment
Item generation. Eleven items assessing interfer-
ence in functioning were originally considered for
inclusion in the WIS. These items were arrived at
through interviews with women attending the
BOCREP and from reports in the literature of
putative areas of impaired functioning in women
with family histories of breast cancer (e.g.
Wellisch et al., 1991, 1992). Care was taken to
sample a variety of relevant content areas and to
vary the language used in the phrasing of the
questions. As previously noted, the potential WIS
scale items assessed disruptions in sleep, work,
concentration, relationships, having fun, feeling
sexually attractive, meeting family needs, and re-
productive decisions. Additional items assessed
participants’ abilities to speak with their partners
about their concerns, their partners’ abilities to be
understanding, and frequency of participants’
worries about their children’s or grandchildren’s
chances of developing breast cancer. Pearson
product–moment correlations between all poten-
tial WIS scale items at Time 1 (pre-session) are
presented in Table 2.
Factor analysis. Factor analysis was conducted
in order to reduce the dimension of the data and
create a single scale of perceived Worry Interfer-
ence. In order to create this single summary scale,
a procedure recommended by Tabachnick and
Fidell (1996) was followed, using Principal Com-
ponents Analysis (PCA) on a subset of correlated
items with pairwise correlations above 0.3. Seven
worry interference items assessing dysfunction in
relationships, sleep, work, having fun, feeling sex-
ually attractive, meeting family needs, and con-
centration met this criteria. Analysis of Time 1
data yielded a single factor accounting for 62.7%
of the variance in scores. All seven items loaded
above 0.7 on the factor, and analysis of the scree
plot confirmed the appropriateness of the single-
factor solution. Factor loadings are presented in
Table 3. Confirmatory analyses conducted on
Time 2 data yielded an identical factor solution.
Given the stable factor structure of the scale,
scores on the seven items were summed to yield a
total Worry Interference score, which was used as
a summary measure in all further analyses. Fre-
quency data on WIS total scores are presented in
Table 4.
Scale reliability and internal consistency. The
resulting seven-item scale has excellent internal
consistency, with Cronbach’s alpha coefficients
ranging from 0.89 to 0.94 in random samples of
clinic patients, where scales with an alpha 0.75
are considered internally consistent (Nunnally,
Copyright © 2001 John Wiley & Sons, Ltd. Psycho-Oncology 10: 349–360 (2001)
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Table 3. Factor loading on the WIS
Factor loadingVariable
0.765Relationships
Ability to sleep 0.789
0.828Work
0.845Ability to have fun
0.740Ability to feel sexually attractive
Ability to meet family’s needs 0.785
Ability to concentrate 0.843
functioning assessed. The average interference
score was 10.47, indicating at least minimal inter-
ference in three areas of functioning, or ‘a lot’ of
interference in one area. However, the standard
deviation for this score was 4.58, reflecting a wide
variability in the degree to which women per-
ceived breast cancer-specific worries as disruptive
of their daily activities. The median score was 9,
indicating that approximately half of the women
either perceived at least ‘a little’ interference in
two of the seven areas of functioning assessed, or
greater interference in one area alone.
Group creation. Analyses were then conducted
in relation to a dichotomous representation of
pre-session Worry Interference, with Group 1 in-
cluding patients whose worries did not interfere at
all with their functioning (34.6%) and Group 2
including patients whose worries interfered ‘at
least a little’ in one or more areas of functioning
(66.4%). Comparisons between the two pre-
session Worry Interference groups on baseline
demographic variables such as age, marital status,
religion, ethnicity, and education did not reveal
any significant differences that might explain
higher Worry Interference in some patients.
Correlations with Worry Interference: conergent
alidity
Given the non-normal distribution of scores on
the WIS, in order to perform further analyses
addressing the validity of the new scale, scores
from participants in Group 1 (those indicating no
perceived interference from breast cancer worries)
were dropped out, and subgroup analyses were
conducted on data from Group 2 (i.e. those indi-
cating some perceived Worry Interference). In
order to assess the convergent validity of the new
scale, Pearson product–moment zero-order corre-
lations were conducted on data from the WIS,
POMS, and SF-36. Convergent validity is assessed
based on the associations between similar mea-
sures, with higher correlations indicative of
greater convergent validity. All correlations were
in the expected directions.
Worry Interference scores were significantly
positively correlated with POMS Anxiety (r=
0.331, p=0.016), Depression (r=0.395, p=
0.002), Confusion (r=0.304, p=0.021), and
Total Mood Disturbance (r=0.388, p=0.004).
WIS scores were also significantly negatively
associated with SF-36 scores measuring Mental
1967). Split-half reliabilities range from 0.83 to
0.92 for the first four items and 0.75 to 0.83 for
the last three, where split-half reliabilities of at
least 0.75 are considered internally consistent
(Nunnally, 1967). Test-retest reliability was ade-
quate at r=0.727 from Time 1 to Time 2 for
those women who completed both measures.
Central tendency. Scores on the WIS can range
from a low of 7 if an individual answers ‘not at
all’ to a high of 35 if a participant answers ‘a lot’
to all five items. Respondents’ scores on the de-
vised scale ranged from a minimum of 7, indicat-
ing no interference to a maximum of 34,
indicating significant disruptions in every area of
Table 4. WIS total score frequencies
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Health Functioning (r= −0.273, p=0.007),
Emotional Role Functioning (r= −0.278, p=
0.005), and Physical Role Functioning (r=
−0.200, p=0.045). A trend toward a negative
association with POMS Vigor was also observed
(r= −0.254, p=0.056).
Worry Frequency
As previously noted, how frequently a woman
worried about breast cancer was assessed on a
scale that ranged from ‘never’ to ‘at least daily’.
Results in the current study revealed that 14% of
participants said they never worried about breast
cancer, 20.9% seldom worried, 27.9% worried at
least monthly, 34.9% worried at least weekly, and
2.3% worried daily. Further examination of
Worry Frequency with Group 1 and Group 2
revealed that all women who reported never wor-
rying about breast cancer were in Group 1.
Effects of cancer on Worry Interference
Prior to examining the effects of Worry Inter-
ference on emotional distress and health function-
ing, the impact of a diagnosis or family history of
cancer on Worry Interference was assessed. Chi-
square analyses were conducted comparing partic-
ipants currently diagnosed with breast cancer to
those without a cancer diagnosis. Results indi-
cated that women with breast cancer (whether
invasive or non-invasive) were more likely to be
represented in Group 2 (that is, to have interfer-
ence in their lives from cancer-specific worry:
(2=14.94, p0.001). Chi-square analyses were
then conducted comparing Worry Interference
groups for those whose family members (mothers
and/or sisters) had breast or ovarian cancer with
those who did not. Analyses revealed no signifi-
cant differences in the number of family members
with cancer between these two subgroups.
Effects of Worry Interference
Emotional distress. In order to determine
whether differences in emotional distress existed
between those individuals who reported no inter-
ference from breast cancer worry (Group 1) and
those who perceived some interference (Group 2),
POMS scale scores (Anxiety, Depression, Anger,
Vigor, Fatigue, Confusion) and Total Mood Dis-
turbance score were subjected to one-way analysis
of variances (ANOVAs) by group. Results re-
vealed that Anxiety, F(1,81)=6.22, p0.015,
and Confusion, F(1,91)=8.90, p0.004, were
significantly different for the two groups. Ob-
served means indicated that individuals in Group
2 (those whose worry interfered with their func-
tioning) reported higher levels of anxiety and
confusion. ANOVAs on the remaining scales did
not detect statistically significant differences be-
tween Worry Interference groups.
Of interest was whether the observed effects of
Worry Interference on emotional distress re-
mained significant after consideration of the
effects of other variables. In particular, demo-
graphic variables such as having a personal or
family history of breast or ovarian cancer, or
psychological variables, such as the frequency of
the respondent’s worry about cancer could ac-
count for some of the effects noted above. In
order to address this, analyses were conducted
with age, education, religion, ethnicity, marital
status, and Worry Frequency scores as indepen-
dent variables in bivariate regressions with POMS
Anxiety and POMS Confusion as dependent vari-
ables. Any variable associated with scores on
either POMS Anxiety or POMS Confusion at
p0.10 was to be controlled for in a multiple
hierarchical regression model with Worry Inter-
ference. None of the potential confounding vari-
ables were associated with scores on the
dependent variables of interest at p0.10. Bivari-
ate regression analyses were, therefore, conducted
separately on POMS Anxiety and Confusion with
Worry Interference as the independent variable.
Worry Interference was significantly associated
with POMS Anxiety F(1,81)=6.643, p0.012
and POMS Confusion F(1,91), p0.014.
Health functioning. The two Worry Interference
groups were also compared using oneway
ANOVAs on the SF-36 scales using the trans-
formed scores. The groups differed significantly
on the Role–Emotional, F(1,159)=9.59, p
0.002, and Mental Health, F(1,154)=9.65, p
0.002, scales. Individuals whose worries interfered
‘at least a little’ with their daily functioning re-
ported lower levels of mental health and role
functioning. The remaining SF-36 scales did not
differ significantly between the two groups.
As with the POMS scales, significant SF-36
scales were subjected to bivariate regressions to
determine whether Worry Interference was
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significantly associated with health functioning
after accounting for potential confounding vari-
ables. Bivariate regressions with Worry Interfer-
ence as the independent variable and SF-36
Role–Emotional as the dependent variable
yielded significant results, F(1,158)=23.765, p
0.0001, as did regressions with SF-36 Mental
Health, F(1,154)=10.629, p0.001. However,
regressions with Worry Frequency as the indepen-
dent variable also yielded results indicative of
potentially significant associative value: with SF-
36 Role–Emotional, F(1,168)=5.558, p0.02;
with SF-36 Mental Health, F(1,164), p0.053.
As a result, hierarchical multiple regressions were
conducted on each of the two SF-36 scales of
interest, with Worry Frequency and Worry Inter-
ference as independent variables. Worry Interfer-
ence was entered into the models sequentially
after Worry Frequency, to see if inclusion of the
interference measure provided incremental asso-
ciative utility over simple frequency, since this is
the more parsimonious and easily measured of the
two constructs. For Role–Emotional, Worry Fre-
quency entered on the first step yielded significant
results, F(1,157)=6.1, p0.015. The addition of
worry interference on the second step accounted
for significantly more of the variance in scores on
the criterion, F(1,156)=16.561, p0.0001. Only
Worry Interference explained a significant
amount of the variance in Role–Emotional scores
in the full model; the effects of Worry Frequency
dropped out (p= −0.012, ns). With regard to
Mental Health functioning, Worry Frequency as
the only predictor variable did not explain a
significant amount of the variance in scores on the
scale, F(1,154)=2.073 ns. The addition of Worry
Interference explained significant incremental
variance in scores on the criterion, F(1,153)=
8.642, p0.004, and brought the full model to
significance, F(2,153)=5.409, p0.005.
DISCUSSION
The current study was designed to assess the
utility of an investigator-derived measure of per-
ceived interference from cancer-specific worries
and intrusive thoughts. Validity data indicate that
the measure correlates as expected with measures
of distress and dysfunction across a number of
areas. Additionally, analyses using a cut-off score
to distinguish individuals whose worries interfered
with their functioning from those who reported
no interference revealed significant differences in
mood and functioning between the two groups.
Specifically, women whose worries interfered
with their functioning were generally more dis-
tressed as demonstrated by reduced ratings of
their mental health functioning on the SF-36.
However, using a more specific multi-dimensional
scale, current results indicated that they reported
higher levels of POMS anxiety and confusion, but
not depression or anger. This suggests that the
interference from cancer-specific worries experi-
enced by participants in this study may be more a
function of anxiety and mild cognitive dysfunc-
tion, than general distress. Additionally, women
who perceived interference in their functioning as
a result of cancer-specific thoughts also reported
more limitations in performing their usual roles in
and outside the home, as demonstrated by lower
Role–Emotional scores on the SF-36. This indi-
cates that the scale was effective in distinguishing
women reporting impairments in their abilities to
fulfill their usual responsibilities at home and at
work from those reporting no such impairments.
Furthermore, the new measure was found to
predict distress and functioning scores when other
background variables that have been reported to
be associated with distress, such as having a per-
sonal or family history of cancer, did not. The
measure also predicted scores on the SF-36 be-
yond the effects of frequency of worry about
breast cancer. This is an important point, since it
indicates that it is more than the amount of time
participants spent worrying about getting breast
cancer that predicted their functioning. Rather,
the increased information contained within the
WIS had predictive value beyond simply how
much time they worry about cancer.
When interpreting the results reported here,
several caveats should be considered. First, the
study utilized a cross-sectional design that means
that all associations are correlational, and there-
fore, no claims toward causality can be made.
Any references to prediction in the current paper,
therefore, refer to statistical prediction, not tem-
poral prediction. It may be that anxiety, confu-
sion, and impaired role functioning precede the
occurrence of thoughts about breast cancer
among women referred to the BOCREP. If this
proves to be the case, the areas of dysfunction
found in the current study would not be the result
of experiencing cancer-specific worry and
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intrusive thoughts, but the reverse. It is also possi-
ble that a third factor, unaccounted for in the
current study could cause variations in both cog-
nitive processes and dysfunction. Given this, more
research is necessary to determine the potential
temporal direction of the associations between
cancer-specific thoughts and perceived related
dysfunction. Longitudinal studies using path
analyses will be useful in future work to test the
hypothesis that cancer-specific worry or intrusive
thoughts in fact precede and/or cause dysfunction.
Second, although the fact that participants were
referred for services rather than recruited for re-
search purposes allows generalization of the re-
sults to other high-risk clinics, the relative lack of
ethnic and economic diversity of the sample limits
the generalizability of results to other popula-
tions. In particular, the predominantly white and
well-educated sample diminishes the potential ap-
plicability of the results to the larger population
of individuals at risk for breast or ovarian cancer.
Future efforts could be aimed at actively seeking
referrals from sources with a more ethnically and
economically diverse population base to remedy
this.
Third, more research is also needed to develop
a better understanding of the cognitive and be-
havioral processes in which many women at risk
engage. To this end, associations of the WIS with
the Impact of Events Scale (IES) (Horowitz et al.,
1979) could prove useful. The IES, a measure that
has been used extensively in research to assess the
presence of intrusive thoughts and avoidance re-
lated to genetic testing, having cancer, and being
at increased risk for cancer, primarily assesses for
the presence of intrusive thoughts and avoidant
behaviors following a traumatic event. The pur-
pose of the current paper was to introduce and
validate a new measure of the interference per-
ceived to be caused by cancer-specific thoughts,
and as such did not utilize the IES. Future re-
search with both measures may help lead to a
more sophisticated understanding of the anxiety
experienced by many women at risk, so that max-
imally useful interventions and counseling tech-
niques might be developed. More research is
needed to distinguish specifically the cognitive
events experienced by these women from the emo-
tions they experience, the behaviors in which they
engage, and the impairments in functioning they
experience.
Further research will also be useful in determin-
ing whether the disruptions in daily life function-
ing (in relationships, sleep, work, ability to have
fun, feel sexually attractive, concentrate, and meet
family needs) perceived to be the result of cancer-
specific thoughts are associated with effects on
health behaviors, risk perception, or decisional
outcomes. There is evidence that cancer-related
worries are predictive of adherence to recommen-
dations for mammography screening (Stefanek
and Wilcox, 1991; McCaul et al., 1996; Diefen-
bach et al., 1999), breast self-examination (Kash
et al., 1992; Brain et al., 1999), and clinical breast
examination (Kash et al., 1992). However, the
direction of this association remains equivocal; it
may be that Worry Interference plays a moderat-
ing role in distinguishing women who adhere to
screening practices from those who do not.
Finally, the association of Worry Interference
scores with increased cognitive dysfunction, as
measured by the POMS Confusion scale implies
that women at risk do not feel they are function-
ing cognitively at an optimal level. Such dys-
function could be associated with difficulties par-
ticipating fully in the genetic counseling process,
and in impairments in decision-making, including
decisions to have genetic testing or to take
prophylactic measures. Evidence exists that
anxiety affects decision-making in experimental
paradigms (Raghunathan and Pham, 1999), and
may play a role in medical decision-making, in-
cluding selection of prophylactic mastectomy
(Margalith and Shapiro, 1997; Karp et al., 1999;
Stefanek et al., 1999). If anxiety is interfering in
the counseling and decision-making process, the
potential exists for it to be reduced or avoided
if appropriate interventions can be designed.
Specific cognitive–behavioral strategies for deal-
ing with anxious intrusions and worries that have
proven efficacy in clinical settings (e.g. Barlow et
al., 1998) may prove useful if adapted for use with
this population. Additional research aimed at un-
derstanding further the cancer-specific cognitions
and related areas of dysfunction experienced by
women at risk may help to identify methods of
alleviating their anxiety, improving their function-
ing, and maximizing their satisfaction with the
genetic counseling and testing process.
Results from this study add to the expanding
area of anxiety/distress and genetic testing issues
in at-risk populations. Specifically, they address
directly the issue of perceived interference from
‘cancer-specific’ worry or intrusive thoughts,
using a measure designed specifically for that
purpose. Results confirm previous research
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indicating the presence of cancer-specific worry/
intrusive thoughts and add empirical support to
clinical reports of perceived disruptions in func-
tioning as a result. These findings have implica-
tions for literatures on both worry/intrusive
thoughts and genetic testing.
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